Gerresheimer AG Q3 revenue up 9.2% to 311.4 mln euros

By Admin
Gerresheimer AG reported 9.2% rise in its revenue to 311.4 million euros for the third quarter. The German pharma and healthcare industry supplier stat...

Gerresheimer AG reported 9.2% rise in its revenue to 311.4 million euros for the third quarter. The German pharma and healthcare industry supplier stated it reported lower profit for the third quarter as the increase in expenses more than offset increased revenues.  But, the company maintained its full year forecasts. 

Net income dipped 25% to 14.4 million euros ($18.62 million) from 19.2 million euros. The adjusted net income was lower by 10.9% at 20.7 million euros.  The adjusted Earnings before interest, taxes, depreciation and amortization (EBITDA) was 19.5% in the quarter, while it stood at 20.0% last year.  

On the constant currency basis, the revenue growth was 6.3%.  The tubular glass revenue surged nearly 11% to 84.6 million euros. Revenue from plastic systems improved 3.5% to 107 million euros.

Meanwhile, moulded glass revenues rose 11.6% from last year at 95.6 million euros.  The life science research revenues rose around 18% to 27.7 million euros.  Furthermore, sales of pharmaceutical plastic packaging products in South America developed really well. 

The German pharma and healthcare industry supplier also achieved good growth in sales of vials, flacons and jars for the cosmetic and pharmaceutical industries. Besides, the demand for self-medication and diagnostic products like asthma inhalers, insulin pens and lancing devices for the diabetics also was high. 

Gerresheimer AG is a manufacturer of high-quality specialty products made of glass and plastic for the healthcare and pharma industry. Its portfolio of products includes pharmaceutical vials to complex drug delivery systems like the syringe systems, insulin pens and inhalers for safe medication dosage and application.

Share
Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19